Slashing 186 jobs, Novartis hands off U.S. sales, marketing duties for migraine med Aimovig to Amgen

Novartis and Amgen were the first onto the CGRP scene with migraine drug Aimovig, but tensions ensued shortly into the drug's launch as both partners filed dueling lawsuits against each other. But now with the migraine market becoming increasingly crowded, Novartis will cede U.S. Aimovig operations over to Amgen.